SecBot SecBot

INKT

MiNK Therapeutics, Inc.
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0001840229 Biotech & Drug Discovery
$9.35 +0.01 (+0.11%)
Nov 16 4:00 PM ET · prev $9.34
Market cap
$48.9M
Nano cap
Consensus
Buy
88% Buy or better · 8 analysts
Median target
$44.00
+371% · range $38.00–50.00
1 year
−22.1%
from $12.00 · Nov 17
30 days
−2.2%
from $9.56
52-week range
$8.56–14.21
−34% from high · low Mar 24
Avg volume 20D
12.2K
shares / day
Short interest
55.1K
≈1.1% of shares · +15.3%
Days to cover
4.3
at average volume
Insider net
−$119.9K
0 buyers · 2 sellers · 12 mo
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
10
analyzed by SecBot
SecBot read MIXED 5 reports · 90 days
Balance 0 bearish · 0 bullish · 5 neutral oldest → newest, height = score
Avg score ·High conf. 3/5

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    2 insiders sold $119.9K.

  • InstitutionsMIXED

    Q3 2026: 3 added (0 new), 1 trimmed or exited.

  • AnalystsBULLISH

    7 of 8 rate it Buy or better. Every target is above the price.

  • EstimatesFLAT

    Current-quarter EPS estimate −$0.660 → −$0.670 over 90 days. 1 up, 0 down in 30 days.

  • Short sellersBUILDING

    Short interest +15.3% to 55.1K shares. 4.3 days to cover, ≈1.1% of shares.

  • TrendDOWNTREND

    15% below its 50-day average.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
VANGUARD FIDUCIARY TRUST COADD13,164$165.2K
UBS Group AGTRIM1,462$18.3K
BlackRock, Inc.DOUBLED13,382$156.4K
UBS Group AGTRIM4,885$57.1K
OSAIC HOLDINGS, INC.DOUBLED117$1.4K
UBS Group AGADD15,202$160.1K
CITIGROUP INCTRIM91$958.00
OSAIC HOLDINGS, INC.NEAR_EXIT1$10.00

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

8 analysts
Buy 88% rate it Buy or better
Strong Buy2Buy5Hold1Sell0Strong Sell0
12-month targets · 2 analysts

Price is below the lowest target. Median implies +371%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Oct 21, 2026B. Riley Securities
REITERATE
REITERATEBuy

Insider ledger

Form 4
$0
bought · 0 insiders
$119.9K
sold · 2 insiders
DateInsiderTypeValue
Oct 12, 2026
Buell Jennifer
Chief Executive Officer
Oct 12, 2026
SELL$73.3K
Oct 11, 2026
Buell Jennifer
Chief Executive Officer
Oct 11, 2026
EXERCISE23,191 sh
Sep 1, 2026
Behner Peter
Director
Sep 1, 2026
AWARD$16.3K
Sep 1, 2026
Ryan Barbara
Director
Sep 1, 2026
AWARD$17.8K
Sep 1, 2026
Holcomb John Bradley
Director
Sep 1, 2026
AWARD$13.5K
Sep 1, 2026
Corvese Brian
Director
Sep 1, 2026
AWARD$17.9K
Sep 1, 2026
WIINBERG ULF
Director
Sep 1, 2026
AWARD$14.0K
Jun 4, 2026
Ryan Barbara
Director
Jun 4, 2026
SELL$6.3K

Earnings setup

Estimates
−$0.67
EPS estimate, this quarter
−2%
estimate change, 90 days
1↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.67-$0.71–-$0.63-71.8%$0.00
Next QNoneNoneNo data$0.00
Current FY-$2.45-$2.58–-$2.32-26.9%$0.00
Next FY-$0.72-$0.72–-$0.72+63.5%$0.00

Short side

FINRA· Oct 30, 2026
55,094
shares short
+15.3%
vs prior settlement
4.3
days to cover
≈1.1%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 12, 2026 SEC
MiNK Therapeutics reported Q3 2026 net loss of $2.6M ($0.50/share), a 23% year-over-year improvement from $2.9M…
8-K · Impact 4/10
Nov 11, 2026 SEC
MiNK Therapeutics reported Q3 2026 net loss of $2.6M ($0.50 per share), narrower than the $2.9M loss ($0.65 per share)…
PRESS-RELEASE · Impact 4/10
Nov 11, 2026 Earnings
MiNK Therapeutics Reports Third Quarter 2026 Results, First Pre-Commercial Product Revenue from agenT-797, Randomized ARDS Trial Advancing, and ARPA-H Selection for Deployable Cell Therapies
NEW YORK, Nov. 11, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT) , a clinical-stag
Nov 2, 2026 SEC
MiNK Therapeutics announced it will report Q3 2026 financial results on November 11, 2026, before market open. The…
PRESS-RELEASE · Impact 2/10
Oct 12, 2026 Insider
Buell Jennifer sold 6,938 shares
Chief Executive Officer @ $10.56 ($73.3K)
Oct 11, 2026 Insider
Buell Jennifer acquired via exercise 23,191 shares
Chief Executive Officer
Oct 2, 2026 Press
MiNK Therapeutics presented preclinical data at SITC 2026 showing agenT-797 enables tumor-cell killing in a checkpoint…
Impact 4/10
Sep 30, 2026 Inst.
VANGUARD FIDUCIARY TRUST CO · ADD
13,164 shares ($165.2K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
2 drugs tracked · Drug pipeline →
Recent

SecBot reports

10 filings · 11 press releases · 2 bullish · 0 bearish · 2 mixed · 6 neutral
All INKT filing & press-release reports (21)